Provided are a microorganism for producing a pantoic acid, and a construction method therefor and an application thereof. The microorganism for producing the pantoic acid is obtained by knocking out a gene in Escherichia coli and introducing an exogenous gene. The obtained microorganism is Escherichia coli that is registered in the China General Microbiological Culture Collection Center with an accession number of CGMCC No. 21699. A pantoic acid synthesis pathway has been opened up, and accumulation of the pantoic acid can be achieved in a fermentation process.

Compositions for a phage particle are disclosed. The phage particle is non-replicating and includes at least one heterologous nucleic acid sequence that is capable of being expressed in a target bacteria. The expressed heterologous nucleic acid sequence is non-lethal to the target bacteria.

An object of the present disclosure is at least to provide a technique for promoting elimination of a methyl group(s) of a methoxy group(s) in causing a microorganism having a demethylation ability of eliminating a methyl group(s) of a methoxy group(s) from a compound with the methoxy group(s) in a side chain(s) to produce a demethylated compound in which a methyl group(s) of a methoxy group(s) has eliminated from a compound with the methoxy group(s) in a side chain(s). The issue is solved by a method for producing a demethylated compound, comprising co-culturing, in a solution containing a compound with a methoxy group(s) in a side chain(s), a microorganism having a demethylation ability of eliminating a methyl group(s) of a methoxy group(s) from a compound with the methoxy group(s) in a side chain(s), and a microorganism having an activity to promote the demethylation, to produce the demethylated compound in which a methyl group(s) of a methoxy group(s) has eliminated from the compound with the methoxy group(s) in the side chain(s).

Compositions for a phage particle are disclosed. The phage particle is non-replicating and includes at least one heterologous nucleic acid sequence that is capable of being expressed in a target bacteria. The expressed heterologous nucleic acid sequence is non-lethal to the target bacteria.

The present invention relates to a secretagogue compound derived from oxalate degrading bacteria, for use in the treatment of an oxalate related disease and/or oxalate related imbalance in a subject, wherein the administration of the secretagogue results in a reduction of urinary oxalate and/or plasma oxalate in the subject. The invention further relates to a pharmaceutical composition comprising such a secretagogue compound, a method for treating a subject suffering from an oxalate related disease, and to a method for preparing a secretagogue.

The present disclosure relates to recombinant algae, more particularly to recombinant blue green algae. The disclosure further relates to a method for production of recombinant spider silk protein from the said recombinant algae. The said recombinant algae provides for green technology for the production of spider silk protein. The production of spider silk protein in the said recombinant algae is simple and economical.

The present invention relates to a secretagogue compound derived from oxalate degrading bacteria, for use in the treatment of an oxalate related disease and/or oxalate related imbalance in a subject, wherein the administration of the secretagogue results in a reduction of urinary oxalate and/or plasma oxalate in the subject. The invention further relates to a pharmaceutical composition comprising such a secretagogue compound, a method for treating a subject suffering from an oxalate related disease, and to a method for preparing a secretagogue.

Methods of producing peptide beta-lactones and beta-hydroxy acids are disclosed that include contacting a beta-hydroxy-alpha-amino acid, an aryl carrier protein (ObiD), and ATP with a non-ribosomal protein synthetase. A continuous flow reactor is disclosed that includes an elongate conduit with at least one region that includes a first region with a non-ribosomal protein synthetase immobilized to a substrate. The non-ribosomal protein synthetase of the continuous flow reactor is configured to contact a flow of a reaction mixture that includes a beta-hydroxy-alpha-amino acid and an aryl carrier protein. The non-ribosomal protein synthetase is further configured to release a peptide beta-lactone into the flow of the reaction mixture.

An exemplary embodiment of the present disclosure provides a method of converting formate to a desired compound. The method comprises providing a biocatalyst and formate to form a reaction mixture and reacting at least the biocatalyst with formate to produce a first reaction product.

The present invention relates to a vitamin B6-coupled poly(ester amine) (VBPEA) as a gene carrier and a method for preparing the gene carrier. Moreover, the present invention relates to a gene delivery complex comprising a therapeutic gene coupled to the gene carrier and a pharmaceutical formulation for gene therapy, which comprises the gene delivery complex as an active ingredient. In addition, the present invention relates to gene therapy utilizing the gene carrier, the gene delivery complex or the pharmaceutical formulation. The VBPEA of the invention has a significantly high gene delivery rate compared to existing gene carriers and a complex of the VBPEA with DNA has little or no cytotoxicity and shows a very high in vivo transfection efficiency. In addition, a complex of the VBPEA with siRNA shows high gene silencing efficiency and can induce a high rate of cell death and the inhibition of cell proliferation in cancer cells, suggesting that it can be used for anticancer gene therapy. Thus, the gene carrier VBPEA of the invention can be used as an experimental gene carrier and can also be widely used in gene therapy against various diseases depending on the kind of therapeutic gene.